This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Study reveals how cancer immunotherapy may cause heart inflammation in some patients By Leah Eisenstadt November 6, 2024 Breadcrumb Home Study reveals how cancer immunotherapy may cause heart inflammation in some patients Myocarditis is driven by a different immune response than the anti-tumor one, suggesting that the serious complication could one day be managed without halting cancer therapy.
Inhaled combination products (ICP) have emerged as a significant advancement in the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary conditions. Inhalation offers a targeted route of drug delivery directly to the lungs, minimizing systemic side effects and maximizing therapeutic benefits.
This essay by Kamal Nahas concludes Issue 04 of Asimov Press. In the 1924 novel, The Magic Mountain , Thomas Mann describes a sanatorium patient named Anton Ferge as he undergoes a painful tuberculosis (TB) treatment. “I lie there with my face covered, so I can’t see anything,” Anton says. “I feel myself being pinched and squeezed, that is the flesh they are laying back and pegging down.” Ferge’s harrowing treatment is a lung-flattening artificial pneumothorax
Thomas M. Geiger, Radosław P. Nowak Annual Reports in Medicinal Chemistry , 2024 [link] Proteolysis targeting chimeras (PROTACs) are hetero-bifunctional molecules that remove disease-causing proteins through the means of targeted protein degradation (TPD). Since their proof-of-concept over 20 years ago, PROTACs emerged as new modality in drug discovery and chemical biology.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
A transatlantic collaboration is uncovering the role of key genetic variants in common diseases like type 2 diabetes and obesity By Corie Lok November 4, 2024 Breadcrumb Home A transatlantic collaboration is uncovering the role of key genetic variants in common diseases like type 2 diabetes and obesity The Novo Nordisk Foundation Center for Genomic Mechanisms of Disease brings together Danish and Broad scientists.
Alzheimer's disease (AD) is a progressive age-related neurodegenerative brain disorder that destroys memory and other important mental functions. This review article comprehensively summarized the recent advancements in galantamine and its hybrid analogs as potential therapeutic agents for the management of AD. Furthermore, we also provided the design, synthesis, and SAR analysis of the galantamine-based compounds used in the last decades for the management of AD.
In today’s world, creating an inclusive healthcare environment that caters to the needs of individuals with cognitive disabilities is crucial. Universal design principles aim to make healthcare accessible and effective for all, regardless of cognitive ability. In this post, we’ll explore how universal design can be applied to healthcare systems to support individuals with cognitive disabilities.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
In today’s world, creating an inclusive healthcare environment that caters to the needs of individuals with cognitive disabilities is crucial. Universal design principles aim to make healthcare accessible and effective for all, regardless of cognitive ability. In this post, we’ll explore how universal design can be applied to healthcare systems to support individuals with cognitive disabilities.
W Liu, R Patouret, E Peev, S Barluenga, N Winssinger Helvetica Chimica Acta , 2024 [link] Herein, we detail an extension of our research on the synthesis of a small library of furanoheliangolides and the characterization of the covalent interaction between goyazensolide and IPO5. Using a build‐couple‐pair strategy, we assembled a small library of germacrene‐type lactones and diversified them into eight groups of structurally different analogues.
Case Study: How to Ensure Safety While Manufacturing Highly Potent APIs aasimakopoulos Mon, 11/04/2024 - 17:37 Highly potent active pharmaceutical ingredients (API) require careful attention to safety and handling during formulation and manufacturing. This blog explores the process required for manufacturing a highly potent API for an ophthalmic indication, based on a case study involving loteprednol etabonate, a topical corticosteroid used to treat eye inflammations.
Introduction Therapeutic antibodies have proven to be indispensable medicines for addressing the most debilitating diseases. These specialised proteins exhibit a remarkable ability to recognise and bind with high specificity to antigens. Their unique affinity and selectivity make them invaluable for scientists striving to unravel the complexities of biology and disease at a molecular level, paving the way for innovative therapeutic strategies and medical advancements.
In preparation for World Orphan Drug Congress Europe, we interviewed Nathan Chadwick, Senior Director, Therapeutic Strategy Lead, Rare Disease, and Derek Ansel, MS, LCGC, Vice President, Therapeutic Strategy Lead, Rare Disease, to hear their insights into the current progress in rare disease research and their hopes for 2025. What was the biggest development in rare disease in 2024, and how has that impacted clinical research or patient outcomes?
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Mengzhen Gu, Xiaoqing Xu, Xiaoping Wang, Yun Wang, Yu Zhao, Xiaoxian Hu, Lu Zhu, Zhenzhong Deng, and Chao Han Journal of Medicinal Chemistry 2024 DOI: 10.1021/acs.jmedchem.4c02277 Histone lysine-specific demethylase 1 (LSD1) is hyperactive in breast cancer, which is associated with the metastasis of the tumor. Current irreversible LSD1 inhibitors are all synthesized by covalently binding to the flavin adenine dinucleotide cofactor, which often have side effects due to the high affinity for a var
Artificial intelligence (AI) is poised to affect every aspect of the world economy and play a significant role in the global financial system, leading financial regulators around the world to take various steps to address the impact of AI on their areas of responsibility. The economic risks of AI to the financial systems include everything from the potential for consumer and institutional fraud to algorithmic discrimination and AI-enabled cybersecurity risks.
By Jennifer D. Newberger — Though digital health is not new, it can still often be difficult to determine with precision the regulatory requirements applicable to a particular software product. Sometimes this is because FDA has not opined on a specific set of facts, but more often it is because FDA seems to take different approaches to the same technology offered by different companies.
Hydrogen, a promising fuel, has extensive applications in many sectors. However, its safe and widespread use necessitates reliable sensing methods. While tunable diode laser absorption spectroscopy (TDLAS) has proved to be an effective gas sensing method, detecting hydrogen using TDLAS is difficult due to its weak light absorption property in the infrared region.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Jinhyuk Kim, Hadong Kim, Jongwan Kim, Seon Yeon Cho, Sungho Moon, Youngki Yoo, Hanseong Kim, Jin Kwan Kim, Hyejin Jeon, Wan Namkung, Gyoonhee Han, and Kyoung Tai No Journal of Medicinal Chemistry 2024 DOI: 10.1021/acs.jmedchem.4c01393 I n the Hippo signaling pathway, the palmitoylated transcriptional enhanced associated domain (TEAD) protein interacts with the coactivator Yes-associated protein/PDZ-binding motif, leading to transcriptional upregulation of oncogenes such as Ctgf and Cyr61.
Here on Drug Channels , we have long highlighted the boom in provider-administered biosimilars. In contrast to the pharmacy market, adoption of these biosimilars is growing, prices are dropping, and formulary barriers continue to fall. Novel transparency information reveals that this good news doesn’t always translate into savings. Below, we rely on a unique data set from Turquoise Health to examine how much four national commercial health plans—Aetna, Anthem, Cigna, and UnitedHealthcare—paid ho
The development and approval of biosimilars have become increasingly important in the biopharmaceutical industry, offering cost-effective alternatives to original biological medicines. However, biosimilars pose unique challenges in terms of risk management due to their complex nature and potential for immunogenicity.
Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is building on that foundation by taking the drugmaking technology in new directions.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
It's common knowledge that our brains -- and, specifically, our brain cells -- store memories. But a team of scientists has discovered that cells from other parts of the body also perform a memory function, opening new pathways for understanding how memory works and creating the potential to enhance learning and to treat memory-related afflictions.
Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx. Chris examines three key trends that will affect patient support programs: the Inflation Reduction Act (IRA), legal/regulatory battles over copay adjustment programs, and uncertainties following a national election. He then outlines three actions that should guide manufacturers' preparation.
The rising cost of prescription drugs has become a significant public health concern, with millions of Americans struggling to afford their medications. One crucial factor in mitigating this issue is the increased use of generic drugs. Generic drugs have been instrumental in reducing healthcare costs, and their impact cannot be overstated.
THURSDAY, Nov. 7, 2024 -- More than a year after its advisory panel unanimously declared the drug phenylephrine to be useless against nasal congestion, the U.S. Food and Drug Administration is proposing that it be removed from common.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
When Mount St. Helens erupted in 1980, lava incinerated anything living for miles around. As an experiment, scientists dropped gophers onto parts of the scorched mountain for only 24 hours. The benefits from that single day were undeniable and still visible 40 years later.
The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J's Carvykti has in other tests, although Wall Street analysts were divided on how the two drugs compare.
FRIDAY, Nov. 8, 2024 -- Researchers think they’ve figured out why cancer treatments that harness a person’s immune system to fight a tumor can cause heart damage in rare instances.Further, what they’ve learned sheds light on how this potentially dea.
When people have an audience watching them, it can change their performance for better or worse. Now, researchers have found that chimpanzees' performance on computer tasks is influenced by the number of people watching them. The findings suggest that this 'audience effect' predates the development of reputation-based human societies, the researchers say.
Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Now, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving" treatment landscape.
MONDAY, Nov. 4, 2024 -- Alzheimer’s disease patients prescribed fistfuls of daily drugs are at greater risk of harm, a new study warns.Patients with Alzheimer’s prescribed five or more daily medications suffer from more symptoms, falls and hos.
Older people who are sleepy during the day or lack enthusiasm for activities due to sleep issues may be more likely to develop a syndrome that can lead to dementia, according to a new study.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content